Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lianhua Qingke tablet for moderate COVID-19 (ChiCTR2300074231)
ChiCTR2300074231Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Aug 2023
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing basic treatment + Lianhua Qingke tablet with Control: basic treatment + placebo (2 arms). Primary endpoint: Rate of disappearance of cough symptoms. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
Lianhua Qingke
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300074231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074231.